Samsung Bioepis' 5 Biosimilars Achieve $300 Million Overseas Sales in 1Q, Up 2.5%

[Asia Economy Reporter Chunhee Lee] Samsung Bioepis's five biosimilars (biopharmaceutical generics) continued their sales growth by achieving approximately $300 million in overseas sales in the first quarter.

Samsung Bioepis announced on the 6th that the first-quarter overseas sales of its five biosimilars sold through overseas marketing partners reached $292.3 million (approximately 354.4 billion KRW). This represents a 2.5% increase compared to $285.1 million in the same period last year.

Samsung Bioepis sells three autoimmune disease treatments (▲Renflexis (European launch name Flixabi) ▲Brensys (Benepali) ▲Hadlima (Imraldi)) and two anticancer agents (▲Ontruzant ▲Avsola) biosimilar products in collaboration with marketing partners such as Organon and Biogen.

Accordingly, Samsung Bioepis has continuously disclosed the combined sales results of its overseas partners. Biogen and Organon announced their first-quarter results on the 3rd and 5th (local time), respectively. However, these sales figures do not directly translate into Samsung Bioepis's revenue. Under partnership agreements, the amounts received are calculated at a certain ratio and recorded as Samsung Bioepis's actual sales.

By company, Biogen, which supplies the three autoimmune disease treatments to Europe, recorded sales of $194.3 million (approximately 235.6 billion KRW), a 5.3% decrease compared to the same period last year. On the other hand, Organon, which sells all five biosimilars, achieved sales of $98 million, marking a 22.5% growth.

A Samsung Bioepis official stated, "We are expanding product sales in the global autoimmune disease treatment and anticancer drug markets," adding, "This year, we plan to establish a foundation for continuous growth by pioneering the ophthalmic disease treatment market."

Samsung Bioepis aims to launch the biosimilar of the ophthalmic disease treatment 'Lucentis,' called 'Byooviz (SB11),' in the U.S. market this year. In this regard, they have signed a license agreement to allow sales starting from June, before the expiration of the supplementary protection certificate (SPC) held by Genentech. Accordingly, they plan to supply Byooviz worldwide, beginning with U.S. sales through Biogen after June.

This content was produced with the assistance of AI translation services.